Cargando…

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection

Detalles Bibliográficos
Autores principales:	Sun, Fangfang, Lin, Yanwei, Wang, Xiaodong, Gao, Yuan, Ye, Shuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282758/ https://www.ncbi.nlm.nih.gov/pubmed/35843259 http://dx.doi.org/10.1016/S1473-3099(22)00430-3

Ejemplares similares

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
por: Choi, Bina, et al.
Publicado: (2020)

SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients
por: Scherer, Erin M., et al.
Publicado: (2022)

Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection
por: Reuken, Philipp A., et al.
Publicado: (2021)

Hospitalisation associated with SARS-CoV-2 delta variant in Denmark
por: Bager, Peter, et al.
Publicado: (2021)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)

Association between sex and SARS-CoV-2 infection and hospitalisation as a result of COVID-19
por: Adir, Yochai, et al.
Publicado: (2021)

Risk of hospitalisation and death in children with SARS-CoV-2 delta (B.1.612.2) infection
por: Thelwall, Simon, et al.
Publicado: (2022)

Mathematical model of SARS-CoV-2 immunity predicts Paxlovid rebound
por: Ranard, Benjamin L., et al.
Publicado: (2023)

Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection
por: Fishbane, Steven, et al.
Publicado: (2022)

In Silico Evaluation of Paxlovid’s Pharmacometrics for SARS-CoV-2: A Multiscale Approach
por: Bartha, Ferenc A., et al.
Publicado: (2022)

WHO International Standard for anti-SARS-CoV-2 immunoglobulin
por: Kristiansen, Paul A, et al.
Publicado: (2021)

On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
por: Boretti, Alberto
Publicado: (2023)

Prevalence and Course of SARS-CoV-2 Infection among Immunocompromised Children Hospitalised in the Tertiary Referral Hospital in Poland
por: Kuczborska, Karolina, et al.
Publicado: (2021)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

SARS-CoV-2 Infection in Children
por: Lu, Xiaoxia, et al.
Publicado: (2020)

Predicting the risk of chest radiograph abnormality 12-weeks post hospitalisation with SARS CoV-2 PCR confirmed COVID-19
por: Wallis, Tim JM, et al.
Publicado: (2022)

SARS-CoV-2 in immunocompromised individuals
por: DeWolf, Susan, et al.
Publicado: (2022)

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection
por: Lin, Qingqing, et al.
Publicado: (2020)

Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation
por: Wang, Pei-Gang, et al.
Publicado: (2020)

SARS-CoV-2 shedding and infectivity
por: Atkinson, Barry, et al.
Publicado: (2020)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023)

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Establishment of human distal lung organoids for SARS-CoV-2 infection
por: Wang, Ting, et al.
Publicado: (2021)

Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
por: Li, Yixian, et al.
Publicado: (2023)

SARS-CoV-2 infection in conjunctival tissue
por: Liu, Yu-Chi, et al.
Publicado: (2020)

Dysbiosis in SARS-CoV-2–Infected Patients
por: Marazzato, Massimiliano, et al.
Publicado: (2021)

Arthritis after SARS-CoV-2 infection
por: Baimukhamedov, Chokan, et al.
Publicado: (2021)

Neuropathology associated with SARS-CoV-2 infection
por: Glatzel, Markus, et al.
Publicado: (2021)

Neuropathology associated with SARS-CoV-2 infection
por: Egervari, Kristof, et al.
Publicado: (2021)

Neuropathology associated with SARS-CoV-2 infection
por: Nasrallah, MacLean P, et al.
Publicado: (2021)

SARS-CoV-2 reinfection in two patients who have recovered from COVID-19
por: Zhang, Kang, et al.
Publicado: (2020)

SARS-CoV-2 vaccination in the immunocompromised host
por: Connolly, Caoilfhionn M., et al.
Publicado: (2022)

A sustainable synthesis of the SARS-CoV-2 M(pro) inhibitor nirmatrelvir, the active ingredient in Paxlovid
por: Kincaid, Joseph R. A., et al.
Publicado: (2022)

Increased morbidity of obese mice infected with mouse-adapted SARS-CoV-2
por: Zhang, Ya-Nan, et al.
Publicado: (2021)

Single‐center study of outcomes of patients with hairy cell leukemia who contracted SARS‐CoV‐2
por: Annunzio, Kaitlin, et al.
Publicado: (2023)

Experience Using Paxlovid for Patients With Coronavirus Disease 2019 in a Resource-Limited Emergency Department
por: Nene, Rahul V., et al.
Publicado: (2022)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dthpedggjqrrj8m8ds9op8jqs2